首页> 外文期刊>JAMA: the Journal of the American Medical Association >Live vaccine against measles, mumps, and rubella and the risk of hospital admissions for nontargeted infections
【24h】

Live vaccine against measles, mumps, and rubella and the risk of hospital admissions for nontargeted infections

机译:针对麻疹,腮腺炎和风疹的活疫苗以及非针对性感染的住院治疗风险

获取原文
获取原文并翻译 | 示例
           

摘要

IMPORTANCE: In low-income countries, live measles vaccine reduces mortality from causes other than measles infection. Such nonspecific effects of vaccines might also be important for the health of children in high-income settings. OBJECTIVE: To examine whether the live vaccine against measles, mumps, and rubella (MMR) is associated with lower rates of hospital admissions for infections among children in Denmark. DESIGN, SETTING, AND PARTICIPANTS: Population-based cohort study of Danish children born 1997-2006 and followed up from ages 11 months to 2 years (last follow-up, August 31, 2008). Nationwide Danish registers provided data on vaccinations and hospital admissions. The recommended vaccination schedule was inactivated vaccine against diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae type b (DTaP-IPV-Hib) administered at ages 3, 5, and 12 months and MMR at age 15 months. MAIN OUTCOMES AND MEASURES: Incidence rate ratios (IRRs) of hospital admissions for any infection, comparing receipt of MMR vs DTaP-IPV-Hib as the most recent vaccine. Risks, risk difference, and number needed to vaccinate were calculated for receiving MMR on time. RESULTS: The study included 495 987 children contributing with 56 889 hospital admissions for any type of infection during 509 427 person-years (rate, 11.2 per 100 person-years). Receiving the live MMR vaccine after the inactivated DTaP-IPV-Hib-vaccine was associated with a lower rate of hospital admissions for any infection. (Table Presented) The risk of admission for an infection between ages 16 months and 24 months was 4.6% (95%CI, 4.5%-4.7%) for receiving MMR on time and 5.1% (95%CI, 5.0%-5.2%) for not receiving MMR on time. The risk difference was 0.5 percentage point (95%CI, 0.4-0.6), and the number needed to vaccinate with MMR before age 16 months to prevent 1 infectious disease admission was 201 (95%CI, 159-272). CONCLUSIONS AND RELEVANCE: In a cohort of Danish children, receipt of live MMR vs inactivated DTaP-IPV-Hib as the most recent vaccine was associated with a lower rate of hospital admissions for any infections. These findings require replication in other high-income populations.
机译:重要信息:在低收入国家,活麻疹疫苗可降低除麻疹感染以外的其他原因造成的死亡率。疫苗的这种非特异性作用对于高收入地区儿童的健康也可能很重要。目的:研究针对丹麦儿童的麻疹,腮腺炎和风疹(MMR)活疫苗是否与住院率较低相关。设计,地点和参加者:丹麦人群的队列研究,研究对象为1997年至2006年出生的丹麦儿童,随访时间为11个月至2岁(最近一次随访,2008年8月31日)。丹麦全国登记册提供了有关疫苗接种和住院情况的数据。推荐的疫苗接种时间表是灭活的白喉,破伤风,百日咳,脊髓灰质炎和b型流感嗜血杆菌疫苗(DTaP-IPV-Hib),分别在3、5和12个月时接种,MMR在15个月时接种。主要结果和措施:比较任何感染的MMR与DTaP-IPV-Hib的接种情况,比较任何感染入院的发生率(IRR)。计算了按时接受MMR的风险,风险差异和所需疫苗接种数量。结果:这项研究包括495 987名儿童,他们在509 427人年期间因任何类型的感染而接受了56 889例住院治疗(比率,每100人年11.2人)。灭活DTaP-IPV-Hib疫苗后接受活MMR疫苗与任何感染的住院率较低相关。 (显示的表格)准时接受MMR的16个月至24个月年龄之间感染的风险为4.6%(95%CI,4.5%-4.7%)和5.1%(95%CI,5.0%-5.2%) ),原因是未及时收到MMR。风险差异为0.5个百分点(95%CI,0.4-0.6),而在16个月大之前接种MMR疫苗以预防1种传染性疾病的接种人数为201(95%CI,159-272)。结论和相关性:在一组丹麦儿童中,作为最新疫苗接种活MMR与灭活DTaP-IPV-Hib相比,任何感染的住院率均较低。这些发现需要在其他高收入人群中复制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号